TempraMed Technologies (FRA:9DY) Net Margin %: -650.15% (As of Mar. 2026)


FRA:9DY TempraMed Technologies Ltd FRA:9DY
1 GF Score
Price €0.33
! 5 Warning Signs
View Full Analysis

What is TempraMed Technologies Net Margin %?

TempraMed Technologies FRA:9DY -18.63% 1 Net Margin % is -650.15% as of Mar. 2026. GuruFocus rates FRA:9DY with a GF Score™ of 1/100. The stock has 5 warning signs investors should review. Among 818 Medical Devices & Instruments companies, TempraMed Technologies ranks worse than 94.62% on this metric.

Net margin is calculated as Net Income divided by its Revenue. TempraMed Technologies's Net Income for the three months ended in Mar. 2026 was €-2.23 Mil. TempraMed Technologies's Revenue for the three months ended in Mar. 2026 was €0.34 Mil. Therefore, TempraMed Technologies's net margin for the quarter that ended in Mar. 2026 was -650.15%.

The historical rank and industry rank for TempraMed Technologies's Net Margin % or its related term are showing as below:

FRA:9DY' s Net Margin % Range Over the Past 10 Years
Min: -1603.58   Med: -567.65   Max: -148.11
Current: -1603.58

FRA:9DY's Net Margin % is ranked worse than
94.62% of 818 companies
in the Medical Devices & Instruments industry
Industry Median: 2.06 vs FRA:9DY: -1603.58

TempraMed Technologies  (FRA:9DY) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

TempraMed Technologies Net Margin % Related Terms

TempraMed Technologies Net Margin % Historical Data

* Premium members only.

The historical data trend for TempraMed Technologies's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TempraMed Technologies Net Margin % Chart

TempraMed Technologies Annual Data
Trend Dec23 Dec24 Dec25
Net Margin %
0.00 -148.15 -986.98

TempraMed Technologies Quarterly Data
Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only -154.71 0.00 -3,768.86 -364.66 -650.15

FRA:9DY vs ABT, SYK, MDT: Net Margin % Comparison

For the Medical Devices subindustry, TempraMed Technologies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TempraMed Technologies Net Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TempraMed Technologies's Net Margin % distribution charts can be found below:

* The bar in red indicates where TempraMed Technologies's Net Margin % falls into.


FRA:9DY
1GF Score
TempraMed Technologies Ltd FRA:9DY
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TempraMed Technologies Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

TempraMed Technologies's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-15.535/1.574
=-986.98 %

TempraMed Technologies's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.23/0.343
=-650.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -650.15% mean?
TempraMed Technologies (FRA:9DY) has a Net Margin % of -650.15% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on TempraMed Technologies and its competitors. According to the industry distribution chart, TempraMed Technologies ranks #774 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 94.6%.
Is TempraMed Technologies' Net Margin % too high?
TempraMed Technologies' current Net Margin % is -650.15%. Based on the distribution chart, TempraMed Technologies ranks #774 out of 818 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TempraMed Technologies has a GF Score™ of 1/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, TempraMed Technologies ranks #774 out of 818 companies for Net Margin %. This places TempraMed Technologies in the lower half of its industry. The industry median Net Margin % is 2.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.06, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on TempraMed Technologies and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TempraMed Technologies's current Net Margin % is -650.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (FRA:9DY) has a current Net Margin % of -650.15%. The current Net Margin % is -650.15%. TempraMed Technologies' overall GF Score™ is 1/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For TempraMed Technologies (FRA:9DY), the current Net Margin % is -650.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TempraMed Technologies Business Description

Other Exchanges VIVI:Canada
Address Heh B’Iyar 14, Tel-Aviv, ISR, 6209307
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
1GF Score

Get the complete analysis for FRA:9DY

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price